While his character’s finding bravery, there's a lot of bravery in Eric to tell the story as well," said 'Brilliant Minds' ...

The experimental therapy M102 slowed disease progression in preclinical experiments done in mouse and cell models of ALS, a ...

The 2025 Research Innovation Grants are supporting projects focused on biomarkers, risk factors, and treatments for ALS.

Inside the cell reside many tiny assembly factories and warehouses that gather together all of the proteins and RNAs—which ...

The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research ---- The Hoffman ALS Clinical Trial Awards ...

Learn about Amyotrophic Lateral Sclerosis (ALS), its symptoms, risk factors, diagnosis, and current research advancements.

The fight against Amyotrophic Lateral Sclerosis (ALS) has become intensely personal and urgent for hundreds of Indiana ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical trial ...

Eric Dane returns to television with a guest appearance on Brilliant Minds, portraying an ALS patient in a special episode. Here’s a look at his role, the storyline, and how the show integrates his ...

An announcement from Tiziana Life Sciences ( ($TLSA) ) is now available. On November 25, 2025, Tiziana Life Sciences announced that its Phase 2 ...

NeuroSense receives US FDA clearance to begin pivotal phase 3 trial for PrimeC in ALS: Cambridge, Massachusetts Wednesday, November 26, 2025, 13:00 Hrs [IST] NeuroSense Therapeuti ...

Researchers at the University of Toronto's Temerty Faculty of Medicine have found widespread genetic and protein changes in ...